Plasma EET levels were found to correlate with insulin sensitivity, and carriers of a loss-of-function polymorphism in EPHX2(R287Q) demonstrated increased insulin sensitivity, suggesting that EPHX2 inhibition might benefit humans at risk of T2D [8]. Here, EPHX2 is linked to type 2 diabetes mellitus.